OMED - オンコメッド・ファ―マシュ―ティカルズ (OncoMed Pharmaceuticals Inc.) オンコメッド・ファ―マシュ―ティカルズ

 OMEDのチャート


 OMEDの企業情報

symbol OMED
会社名 OncoMed Pharmaceuticals Inc. (オンコメッド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オンコメッド・ファーマシューティカルズ(OncoMed Pharmaceuticals Inc.)は臨床開発段階のバイオ製薬会社。同社は癌幹細胞(CSC)を標的とする単クローン抗体治療薬の発見・開発に取り組む。同社は技術を利用してCSCを識別・隔離・判断、CSCの自己再生・分化に不可欠な各種の潜在的なターゲットと伝達経路を識別・確認、これらのCSCターゲットを調節かつCSCの増殖を阻害する目的で設計された標的抗体と他の蛋白質ベースの治療薬とを開発する。同社の抗がん治療薬はanti-DLL4 (demcizumab OMP-21M18)、Anti-DLL4/Anti-VEGF Bispecific、及びAnti-Notch2/3 (OMP-59R5)、Anti-Notch1 (OMP-52M51) Anti-Fzd7 Fzd8-Fc RSPO-LGRを含む。   オンコメッド・ファ―マシュ―ティカルズは、米国のバイオ製薬会社。がん幹細胞(CSC)を標的とするモノクロ―ナル抗体治療薬を発見、開発する。同社の製品候補は、CSCををタ―ゲットにしており、CSCの自己再生を阻止し、非腫瘍形成状態に向けてCSCの分化を促す。また、バルク腫瘍細胞に影響を与える。   Develops anti-cancer stem cell therapeutics
本社所在地 800 Chesapeake Drive Redwood City CA 94063 USA
代表者氏名 Perry A. Karsen ペリーA.カーセン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-995-8200
設立年月日 38200
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数
url www.oncomed.com
nasdaq_url https://www.nasdaq.com/symbol/omed
adr_tso
EBITDA EBITDA(百万ドル) -11.81500
終値(lastsale) 2.2
時価総額(marketcap) 84703489.2
時価総額 時価総額(百万ドル) 95.29143
売上高 売上高(百万ドル) 40.46400
企業価値(EV) 企業価値(EV)(百万ドル) 15.42543
当期純利益 当期純利益(百万ドル) -11.87900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Oncomed Pharmaceuticals Inc revenues increased 19% to $14.7M. Net loss decreased 75% to $9.6M. Revenues reflect Collaboration revenue increase of 41% to $14.7M. Lower net loss reflects Research and Development - other decrease of 61% to $14.3M (expense) Restructuring charges decrease from $2.4M (expense) to $0K Stock-based Compensation in SGA decrease of 30% to $1.9M (expense).

 OMEDのテクニカル分析


 OMEDのニュース

   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オンコメッド・ファ―マシュ―ティカルズ OMED OncoMed Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)